ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA approves Ayvakit, the first targeted gastrointestinal stromal tumour treatment
January 13, 2020The US Food and Drug Administration (FDA) has approved the kinase inhibitor Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring platelet-derived growth factor receptor alpha (PDGFRA) exo
Pharma Sources Insight January 2025
